Are SGLT2 Inhibitors New Hypertension Drugs?

Circulation. 2021 May 4;143(18):1750-1753. doi: 10.1161/CIRCULATIONAHA.121.053709. Epub 2021 May 3.

Authors

Kazuomi Kario¹, Keith C Ferdinand², Wanpen Vongpatanasin³

Affiliations

¹ Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan (K.K.).
² Tulane University School of Medicine, Tulane Heart and Vascular Institute, New Orleans, LA (K.C.F.).
³ Hypertension Section, Cardiology Division, University of Texas Southwestern Medical Center, Dallas (W.V.).

PMID: 33939525
DOI: 10.1161/CIRCULATIONAHA.121.053709

No abstract available

Keywords: Editorials; drug therapy; hypertension; sodium-glucose transporter 2 inhibitors.

Publication types

Editorial
Comment

MeSH terms

Canagliflozin / adverse effects
Humans
Hypertension* / diagnosis
Hypertension* / drug therapy
Pharmaceutical Preparations*
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

Pharmaceutical Preparations
Sodium-Glucose Transporter 2 Inhibitors
Canagliflozin